1 | conventional | 19,744 |
2 | protocolized | 94 |
3 | reduced-intensity | 72 |
4 | long-course | 70 |
5 | up-front | 49 |
6 | non-myeloablative | 29 |
7 | symptom-triggered | 28 |
8 | wavefront-optimized | 27 |
9 | angiography-guided | 24 |
10 | protocol-directed | 24 |
11 | 25-g | 23 |
12 | non-biological | 23 |
13 | 1-visit | 16 |
14 | single-needle | 16 |
15 | 30-ml | 15 |
16 | multiple-injection | 15 |
17 | placebo-based | 15 |
18 | physician-administered | 14 |
19 | non-modified | 13 |
20 | dual-coil | 12 |
21 | echo-guided | 11 |
22 | formula-based | 11 |
23 | 120-kv | 10 |
24 | n-con | 10 |
25 | nonpreferred | 10 |
26 | once-only | 10 |
27 | physician-driven | 10 |
28 | on-flap | 9 |
29 | standart | 9 |
30 | steroid-based | 9 |
31 | no/minimal | 8 |
32 | non-automated | 8 |
33 | day-patient | 7 |
34 | endoscopic-assisted | 7 |
35 | fasted-state | 7 |
36 | single-surface | 7 |
37 | 12-cm | 6 |
38 | mcinnes | 6 |
39 | non-arb-based | 6 |
40 | standard-volume | 6 |
41 | water-circulating | 6 |
42 | wide-detector | 6 |
43 | clinically-guided | 5 |
44 | convertional | 5 |
45 | dxa-based | 5 |
46 | hysteroscopy-based | 5 |
47 | mmf-based | 5 |
48 | pantogam | 5 |
49 | phosphorylcholine-coated | 5 |
50 | pvc-guided | 5 |
51 | through-the-scope | 5 |
52 | 40-ml | 4 |
53 | b-based | 4 |
54 | full-course | 4 |
55 | in-cell | 4 |
56 | leadbetter-politano | 4 |
57 | mpuv | 4 |
58 | needle-based | 4 |
59 | single-arc | 4 |
60 | small-gauge | 4 |
61 | bcl-xl-targeting | 3 |
62 | compliance-guided | 3 |
63 | continuous-course | 3 |
64 | double-freeze | 3 |
65 | herbal-moxa | 3 |
66 | highly-doped | 3 |
67 | non-acei | 3 |
68 | non-bft | 3 |
69 | personalise | 3 |
70 | physician-prescribed | 3 |
71 | short-incision | 3 |
72 | single-setting | 3 |
73 | third-week | 3 |
74 | three-incision | 3 |
75 | 4.2±1.5 | 2 |
76 | bone-drilling | 2 |
77 | buffy-coat-depleted | 2 |
78 | calcineurin-based | 2 |
79 | ceftazidime-based | 2 |
80 | contemporaly | 2 |
81 | convential | 2 |
82 | even-needling | 2 |
83 | fluid-only | 2 |
84 | fme-based | 2 |
85 | inadapted | 2 |
86 | matched-contact | 2 |
87 | non-modulated | 2 |
88 | non-site | 2 |
89 | one-and | 2 |
90 | partial-dose | 2 |
91 | prostate-only | 2 |
92 | protocol-indicated | 2 |
93 | provider-obtained | 2 |
94 | sandblast | 2 |
95 | single-detector | 2 |
96 | triple-only | 2 |
97 | vectographic | 2 |
98 | 14-3-3beta-specific | 1 |
99 | 16-segments | 1 |
100 | 17.0±14.4 | 1 |
101 | 1932-bp | 1 |
102 | 20-phase | 1 |
103 | 3.8/million | 1 |
104 | 5-mm/min | 1 |
105 | 59,019 | 1 |
106 | 823k | 1 |
107 | androgen-reducing | 1 |
108 | atp-free | 1 |
109 | auricular-point-pressing | 1 |
110 | barrier/no | 1 |
111 | beneficial.although | 1 |
112 | bladder-relaxant | 1 |
113 | cis/tpz | 1 |
114 | crypt-derived | 1 |
115 | decadent | 1 |
116 | diphenhylhydantoin | 1 |
117 | endo-beta-galactosidase | 1 |
118 | evolved-gas | 1 |
119 | eye-closure | 1 |
120 | feet.a | 1 |
121 | freeze-lyophilizing | 1 |
122 | gadobenate-enhanced | 1 |
123 | high-resolution-mass-spectrometry | 1 |
124 | hode | 1 |
125 | hospital-assigned | 1 |
126 | i/not | 1 |
127 | igg/ige | 1 |
128 | individualbased | 1 |
129 | intercropped | 1 |
130 | intra-rv | 1 |
131 | lapped | 1 |
132 | lh-f. | 1 |
133 | lithography-based | 1 |
134 | lysozyme/edta | 1 |
135 | mechanical-biological | 1 |
136 | mevinolin-only | 1 |
137 | microwave-hydrothermal | 1 |
138 | middle-bound | 1 |
139 | mono-antiplatelet | 1 |
140 | non-protein-containing | 1 |
141 | nonacupuncture-related | 1 |
142 | nonlong-acting | 1 |
143 | nspef | 1 |
144 | p-aminobenzoate | 1 |
145 | p/not | 1 |
146 | pipe-flow | 1 |
147 | placebo/prednisolone | 1 |
148 | postdebridement | 1 |
149 | pseudodynamic | 1 |
150 | re-endoscopic | 1 |
151 | royo-salvador | 1 |
152 | second-ranked | 1 |
153 | si-ask1 | 1 |
154 | single-agent-based | 1 |
155 | single-targeting | 1 |
156 | so-based | 1 |
157 | tacrolimus/azathioprine/prednisone | 1 |
158 | therapist-selected | 1 |
159 | tissue-explant | 1 |
160 | top2β-dna | 1 |
161 | transesofagic | 1 |
162 | twodimensional | 1 |
163 | ultra-centrifuge | 1 |
164 | vial/syringe | 1 |
165 | water-submerged | 1 |
166 | written-word | 1 |
1 | 1-visit | 16 |
2 | 12-cm | 6 |
3 | 120-kv | 10 |
4 | 14-3-3beta-specific | 1 |
5 | 16-segments | 1 |
6 | 17.0±14.4 | 1 |
7 | 1932-bp | 1 |
8 | 20-phase | 1 |
9 | 25-g | 23 |
10 | 3.8/million | 1 |
11 | 30-ml | 15 |
12 | 4.2±1.5 | 2 |
13 | 40-ml | 4 |
14 | 5-mm/min | 1 |
15 | 59,019 | 1 |
16 | 823k | 1 |
17 | androgen-reducing | 1 |
18 | angiography-guided | 24 |
19 | atp-free | 1 |
20 | auricular-point-pressing | 1 |
21 | b-based | 4 |
22 | barrier/no | 1 |
23 | bcl-xl-targeting | 3 |
24 | beneficial.although | 1 |
25 | bladder-relaxant | 1 |
26 | bone-drilling | 2 |
27 | buffy-coat-depleted | 2 |
28 | calcineurin-based | 2 |
29 | ceftazidime-based | 2 |
30 | cis/tpz | 1 |
31 | clinically-guided | 5 |
32 | compliance-guided | 3 |
33 | contemporaly | 2 |
34 | continuous-course | 3 |
35 | convential | 2 |
36 | conventional | 19,744 |
37 | convertional | 5 |
38 | crypt-derived | 1 |
39 | day-patient | 7 |
40 | decadent | 1 |
41 | diphenhylhydantoin | 1 |
42 | double-freeze | 3 |
43 | dual-coil | 12 |
44 | dxa-based | 5 |
45 | echo-guided | 11 |
46 | endo-beta-galactosidase | 1 |
47 | endoscopic-assisted | 7 |
48 | even-needling | 2 |
49 | evolved-gas | 1 |
50 | eye-closure | 1 |
51 | fasted-state | 7 |
52 | feet.a | 1 |
53 | fluid-only | 2 |
54 | fme-based | 2 |
55 | formula-based | 11 |
56 | freeze-lyophilizing | 1 |
57 | full-course | 4 |
58 | gadobenate-enhanced | 1 |
59 | herbal-moxa | 3 |
60 | high-resolution-mass-spectrometry | 1 |
61 | highly-doped | 3 |
62 | hode | 1 |
63 | hospital-assigned | 1 |
64 | hysteroscopy-based | 5 |
65 | i/not | 1 |
66 | igg/ige | 1 |
67 | in-cell | 4 |
68 | inadapted | 2 |
69 | individualbased | 1 |
70 | intercropped | 1 |
71 | intra-rv | 1 |
72 | lapped | 1 |
73 | leadbetter-politano | 4 |
74 | lh-f. | 1 |
75 | lithography-based | 1 |
76 | long-course | 70 |
77 | lysozyme/edta | 1 |
78 | matched-contact | 2 |
79 | mcinnes | 6 |
80 | mechanical-biological | 1 |
81 | mevinolin-only | 1 |
82 | microwave-hydrothermal | 1 |
83 | middle-bound | 1 |
84 | mmf-based | 5 |
85 | mono-antiplatelet | 1 |
86 | mpuv | 4 |
87 | multiple-injection | 15 |
88 | n-con | 10 |
89 | needle-based | 4 |
90 | no/minimal | 8 |
91 | non-acei | 3 |
92 | non-arb-based | 6 |
93 | non-automated | 8 |
94 | non-bft | 3 |
95 | non-biological | 23 |
96 | non-modified | 13 |
97 | non-modulated | 2 |
98 | non-myeloablative | 29 |
99 | non-protein-containing | 1 |
100 | non-site | 2 |
101 | nonacupuncture-related | 1 |
102 | nonlong-acting | 1 |
103 | nonpreferred | 10 |
104 | nspef | 1 |
105 | on-flap | 9 |
106 | once-only | 10 |
107 | one-and | 2 |
108 | p-aminobenzoate | 1 |
109 | p/not | 1 |
110 | pantogam | 5 |
111 | partial-dose | 2 |
112 | personalise | 3 |
113 | phosphorylcholine-coated | 5 |
114 | physician-administered | 14 |
115 | physician-driven | 10 |
116 | physician-prescribed | 3 |
117 | pipe-flow | 1 |
118 | placebo-based | 15 |
119 | placebo/prednisolone | 1 |
120 | postdebridement | 1 |
121 | prostate-only | 2 |
122 | protocol-directed | 24 |
123 | protocol-indicated | 2 |
124 | protocolized | 94 |
125 | provider-obtained | 2 |
126 | pseudodynamic | 1 |
127 | pvc-guided | 5 |
128 | re-endoscopic | 1 |
129 | reduced-intensity | 72 |
130 | royo-salvador | 1 |
131 | sandblast | 2 |
132 | second-ranked | 1 |
133 | short-incision | 3 |
134 | si-ask1 | 1 |
135 | single-agent-based | 1 |
136 | single-arc | 4 |
137 | single-detector | 2 |
138 | single-needle | 16 |
139 | single-setting | 3 |
140 | single-surface | 7 |
141 | single-targeting | 1 |
142 | small-gauge | 4 |
143 | so-based | 1 |
144 | standard-volume | 6 |
145 | standart | 9 |
146 | steroid-based | 9 |
147 | symptom-triggered | 28 |
148 | tacrolimus/azathioprine/prednisone | 1 |
149 | therapist-selected | 1 |
150 | third-week | 3 |
151 | three-incision | 3 |
152 | through-the-scope | 5 |
153 | tissue-explant | 1 |
154 | top2β-dna | 1 |
155 | transesofagic | 1 |
156 | triple-only | 2 |
157 | twodimensional | 1 |
158 | ultra-centrifuge | 1 |
159 | up-front | 49 |
160 | vectographic | 2 |
161 | vial/syringe | 1 |
162 | water-circulating | 6 |
163 | water-submerged | 1 |
164 | wavefront-optimized | 27 |
165 | wide-detector | 6 |
166 | written-word | 1 |
1 | lh-f. | 1 |
2 | si-ask1 | 1 |
3 | 17.0±14.4 | 1 |
4 | 4.2±1.5 | 2 |
5 | 59,019 | 1 |
6 | feet.a | 1 |
7 | top2β-dna | 1 |
8 | lysozyme/edta | 1 |
9 | herbal-moxa | 3 |
10 | 14-3-3beta-specific | 1 |
11 | transesofagic | 1 |
12 | vectographic | 2 |
13 | pseudodynamic | 1 |
14 | re-endoscopic | 1 |
15 | single-arc | 4 |
16 | physician-prescribed | 3 |
17 | gadobenate-enhanced | 1 |
18 | pvc-guided | 5 |
19 | compliance-guided | 3 |
20 | echo-guided | 11 |
21 | angiography-guided | 24 |
22 | clinically-guided | 5 |
23 | water-submerged | 1 |
24 | non-modified | 13 |
25 | second-ranked | 1 |
26 | hospital-assigned | 1 |
27 | provider-obtained | 2 |
28 | highly-doped | 3 |
29 | lapped | 1 |
30 | intercropped | 1 |
31 | symptom-triggered | 28 |
32 | physician-administered | 14 |
33 | nonpreferred | 10 |
34 | formula-based | 11 |
35 | dxa-based | 5 |
36 | b-based | 4 |
37 | non-arb-based | 6 |
38 | steroid-based | 9 |
39 | needle-based | 4 |
40 | fme-based | 2 |
41 | ceftazidime-based | 2 |
42 | mmf-based | 5 |
43 | calcineurin-based | 2 |
44 | placebo-based | 15 |
45 | so-based | 1 |
46 | single-agent-based | 1 |
47 | lithography-based | 1 |
48 | hysteroscopy-based | 5 |
49 | individualbased | 1 |
50 | protocol-indicated | 2 |
51 | nonacupuncture-related | 1 |
52 | non-modulated | 2 |
53 | non-automated | 8 |
54 | phosphorylcholine-coated | 5 |
55 | therapist-selected | 1 |
56 | protocol-directed | 24 |
57 | buffy-coat-depleted | 2 |
58 | inadapted | 2 |
59 | endoscopic-assisted | 7 |
60 | crypt-derived | 1 |
61 | protocolized | 94 |
62 | wavefront-optimized | 27 |
63 | one-and | 2 |
64 | middle-bound | 1 |
65 | written-word | 1 |
66 | single-surface | 7 |
67 | hode | 1 |
68 | atp-free | 1 |
69 | igg/ige | 1 |
70 | vial/syringe | 1 |
71 | small-gauge | 4 |
72 | ultra-centrifuge | 1 |
73 | single-needle | 16 |
74 | standard-volume | 6 |
75 | placebo/prednisolone | 1 |
76 | tacrolimus/azathioprine/prednisone | 1 |
77 | through-the-scope | 5 |
78 | eye-closure | 1 |
79 | endo-beta-galactosidase | 1 |
80 | 20-phase | 1 |
81 | personalise | 3 |
82 | partial-dose | 2 |
83 | long-course | 70 |
84 | full-course | 4 |
85 | continuous-course | 3 |
86 | p-aminobenzoate | 1 |
87 | fasted-state | 7 |
88 | non-site | 2 |
89 | non-myeloablative | 29 |
90 | double-freeze | 3 |
91 | nspef | 1 |
92 | 25-g | 23 |
93 | androgen-reducing | 1 |
94 | even-needling | 2 |
95 | bone-drilling | 2 |
96 | non-protein-containing | 1 |
97 | auricular-point-pressing | 1 |
98 | water-circulating | 6 |
99 | nonlong-acting | 1 |
100 | single-targeting | 1 |
101 | bcl-xl-targeting | 3 |
102 | single-setting | 3 |
103 | freeze-lyophilizing | 1 |
104 | beneficial.although | 1 |
105 | non-acei | 3 |
106 | 823k | 1 |
107 | third-week | 3 |
108 | mechanical-biological | 1 |
109 | non-biological | 23 |
110 | convential | 2 |
111 | no/minimal | 8 |
112 | microwave-hydrothermal | 1 |
113 | twodimensional | 1 |
114 | conventional | 19,744 |
115 | convertional | 5 |
116 | dual-coil | 12 |
117 | in-cell | 4 |
118 | 30-ml | 15 |
119 | 40-ml | 4 |
120 | pantogam | 5 |
121 | 12-cm | 6 |
122 | physician-driven | 10 |
123 | 5-mm/min | 1 |
124 | diphenhylhydantoin | 1 |
125 | n-con | 10 |
126 | 3.8/million | 1 |
127 | three-incision | 3 |
128 | short-incision | 3 |
129 | multiple-injection | 15 |
130 | barrier/no | 1 |
131 | leadbetter-politano | 4 |
132 | on-flap | 9 |
133 | 1932-bp | 1 |
134 | royo-salvador | 1 |
135 | wide-detector | 6 |
136 | single-detector | 2 |
137 | evolved-gas | 1 |
138 | mcinnes | 6 |
139 | 16-segments | 1 |
140 | matched-contact | 2 |
141 | mono-antiplatelet | 1 |
142 | non-bft | 3 |
143 | 1-visit | 16 |
144 | tissue-explant | 1 |
145 | bladder-relaxant | 1 |
146 | decadent | 1 |
147 | day-patient | 7 |
148 | postdebridement | 1 |
149 | up-front | 49 |
150 | i/not | 1 |
151 | p/not | 1 |
152 | standart | 9 |
153 | sandblast | 2 |
154 | 120-kv | 10 |
155 | intra-rv | 1 |
156 | mpuv | 4 |
157 | pipe-flow | 1 |
158 | contemporaly | 2 |
159 | fluid-only | 2 |
160 | once-only | 10 |
161 | triple-only | 2 |
162 | prostate-only | 2 |
163 | mevinolin-only | 1 |
164 | high-resolution-mass-spectrometry | 1 |
165 | reduced-intensity | 72 |
166 | cis/tpz | 1 |